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OBJECTIVE—Glycated hemoglobin (HbA1c), used to monitor
and diagnose diabetes, is influenced by average glycemia over a
2- to 3-month period. Genetic factors affecting expression, turn-
over, and abnormal glycation of hemoglobin could also be
associated with increased levels of HbA1c. We aimed to identify such
genetic factors and investigate the extent to which they influence
diabetes classification based on HbA1c levels.
RESEARCH DESIGN AND METHODS—We studied associa-
tions with HbA1c in up to 46,368 nondiabetic adults of European
descent from 23 genome-wide association studies (GWAS) and 8
cohorts with de novo genotyped single nucleotide polymor-
phisms (SNPs). We combined studies using inverse-variance
meta-analysis and tested mediation by glycemia using condi-
tional analyses. We estimated the global effect of HbA1c loci
using a multilocus risk score, and used net reclassification to
estimate genetic effects on diabetes screening.
RESULTS—Ten loci reached genome-wide significant associa-
tion with HbA1c, including six new loci near FN3K (lead SNP/P
value, rs1046896/P  1.6  1026), HFE (rs1800562/P  2.6 
1020), TMPRSS6 (rs855791/P  2.7  1014), ANK1 (rs4737009/
P  6.1  1012), SPTA1 (rs2779116/P  2.8  109) and
ATP11A/TUBGCP3 (rs7998202/P  5.2  109), and four known
HbA1c loci: HK1 (rs16926246/P  3.1  10
54), MTNR1B
(rs1387153/P  4.0  1011), GCK (rs1799884/P  1.5  1020)
and G6PC2/ABCB11 (rs552976/P  8.2  1018). We show that
associations with HbA1c are partly a function of hyperglycemia
associated with 3 of the 10 loci (GCK, G6PC2 andMTNR1B). The
seven nonglycemic loci accounted for a 0.19 (% HbA1c) difference
between the extreme 10% tails of the risk score, and would
reclassify 2% of a general white population screened for
diabetes with HbA1c.
CONCLUSIONS—GWAS identified 10 genetic loci reproducibly
associated with HbA1c. Six are novel and seven map to loci where
rarer variants cause hereditary anemias and iron storage disor-
ders. Common variants at these loci likely influence HbA1c levels
via erythrocyte biology, and confer a small but detectable
reclassification of diabetes diagnosis by HbA1c. Diabetes 59:
3229–3239, 2010
Glycated hemoglobin (HbA1c) results from glyca-tion, the nonenzymatic and mostly irreversiblechemical modification by glucose of hemoglo-bin molecules carried in erythrocytes. The rate
of glycation directly depends on ambient blood glucose
levels, so HbA1c reflects the average concentration of
blood glucose over the average life span of a erythrocyte
(in humans, 3 months), and represents a longer-term
indicator of glycemic status compared to fasting glucose
(FG) (1). In addition to ambient glycemia, it is known that
medical conditions that change erythrocyte turnover (such
as hemolytic anemias, chronic malaria, major blood loss,
or blood transfusion), as well as genetic hereditary ane-
mias and iron storage disorders (caused by rare variants in
genes involved in erythrocyte membrane stability, hemo-
globin function, erythrocyte glucose sensing, and mem-
brane transport) may influence the variability of HbA1c in
populations (2–4).
Common genetic variation also influences HbA1c vari-
ability. The heritability of HbA1c levels is relatively high
(47–59%) when compared with FG (34–36%) or glucose
levels as determined by 2-h postoral glucose tolerance
test (33%) (5,6). Recent genome-wide association stud-
ies (GWAS) of FG have shown that single nucleotide
polymorphisms (SNPs) near three loci (G6PC2,
MTNR1B, and GCK) are also associated with HbA1c
levels (7–15). A GWAS for HbA1c levels in 14,618 nondi-
abetic women found a suggestive association (P  9.8 
108) with SLC30A8 (a known type 2 diabetes locus)
and genome-wide significant association (P  5  108)
at a novel locus, HK1, where rare variants are known to
be associated with nonspherocytic hemolytic anemia
(16). This suggests that both glycemic and erythrocyte
genetic factors are associated with variation in HbA1c,
but a more thorough accounting of common variants
comprising the genetic architecture of HbA1c is needed.
In this study we tested the hypothesis that additional
common genetic factors are associated with HbA1c. We
conducted a meta-analysis of GWAS in up to 46,368
nondiabetic individuals of European ancestry as part of
the Meta-Analyses of Glucose and Insulin-Related Traits
Consortium (MAGIC) effort. In addition to seeking new
common variants affecting HbA1c levels, we sought to
place the size of the effect of novel genetic findings into the
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population perspective of diabetes screening and diagno-
sis. HbA1c levels have recently been recommended for this
use based on high overlap between HbA1c distributions in
populations without diabetes and those with subclinical
(undiagnosed) diabetes, ease of measurement, and an
established role as a treatment target in clinical diabetes
(17,18). We estimated the degree to which these HbA1c-
associated loci shifted the population level distribution
of HbA1c, and thereby influenced diabetes screening
using HbA1c.
RESEARCH DESIGN AND METHODS
Cohort description, study design, and genotyping. The cohorts included
in this study were part of MAGIC (19). The characteristics of the population
samples used in this analysis are shown in Table 1. All participants were adults
of European ancestry from Europe or the U.S., and free of diabetes as
assessed by either clinical diagnosis, self-reported diabetes, diabetes treat-
ment, or undiagnosed diabetes defined by FG 7.0 mmol/l. HbA1c (in
percentages) was measured in all studies from fasting or nonfasting whole
blood using NGSP-certified methods. We found remarkably consistent means
and SD across studies, increasing confidence that laboratory variability had a
minimal effect on the study results. A local research ethics committees
approved all studies and all participants gave informed consent.
We carried out a meta-analysis including 35,920 participants from 23
cohorts with available HbA1c measurements and genotype data including
2.5M genotyped and imputed autosomal SNPs. This sample size ensures
80% power to detect SNPs, explaining 0.12% of the trait variance at   5 
108. For 5 SNPs (rs1046896, rs16926246, rs1799884, rs1800562, and
rs552976) that had been previously selected from an interim analysis of the
first 10 participating cohorts (n  14,898), we obtained further data by
genotyping up to 10,448 participants from 8 additional cohorts. The sample
size for each SNP is thus related to the number of cohorts that were
genotyped (up to 31) and to the specific call rate. Details on genotyping
methodology, quality control metrics, and statistical analyses for each
TABLE 1
Characteristics of 46,368 participants from 31 cohorts employed in the meta-analysis
Cohort
N males/
females
Age (years)
men/women
BMI (kg/m2)
men/women
HbA1C (%, NGSP)
men/women
Fasting plasma
glucose (mmol/l)
men/women
ARIC 3,106/3,671 57.4 (5.7)/56.7 (5.6) 27.33 (3.89)/26.63 (5.30) 5.41 (0.38)/5.37 (0.36) 5.75 (0.50)/5.52 (0.50)
B58C-T1DGC 1,217/1,284 45.3 (0.3)/45.2 (0.3) 27.93 (4.12)/26.86 (5.5) 5.18 (0.48)/5.22 (0.51) —
B58C-WTCCC 711/717 44.9 (0.4)/44.9 (0.4) 27.79 (4.21)/26.84 (5.41) 5.21 (0.68)/5.21 (0.51) —
BLSA 253/235 72.2 (13.5)/67.2 (15.6) 26.99 (3.92)/25.87 (4.94) 5.44 (0.53)/5.45 (0.45) 5.25 (0.56)/4.99 (0.48)
Croatia 275/384 54.8 (15.0)/55.2 (15.8) 27.43 (3.65)/26.94 (4.59) 5.25 (0.49)/5.31 (0.55) 5.40 (0.66)/5.26 (0.65)
deCODE 170/172 66.1 (14.4)/63.8 (16.0) 28.20 (4.00)/28.0 (4.90) 5.80 (0.95)/5.77 (1.25) —
DESIR 178/538 53.1 (5.6)/49.5 (8.5) 23.15 (1.16)/21.36 (1.85) 5.25 (0.38)/5.16 (0.38) 5.11 (0.32)/5.01 (0.38)
DGI 218/262 59.1 (10.6)/59.5 (10.6) 26.42 (3.12)/26.29 (4.29) 5.73 (0.56)/5.61 (0.59) 5.50 (0.52)/5.39 (0.45)
DIAGEN 429/571 59.0 (14.2)/59.0 (15.4) 27.08 (3.61)/26.80 (4.82) 5.59 (0.65)/5.50 (0.61) —
Epic 5,000 1,732/1,627 57.6 (9.4)/54.0 (9.0) 25.75 (2.60)/24.84 (3.38) 5.19 (0.55)/5.08 (0.55) —
EPIC cases 409/548 60.8 (8.9)/60.2 (9.1) 32.55 (2.53)/33.44 (3.24) 5.58 (0.97)/5.47 (0.62) —
EPIC cohort 859/1,052 61.3 (9.3)/60.0 (9.2) 26.79 (3.31)/26.33 (4.36) 5.38 (0.56)/5.32 (0.57) —
Fenland 606/772 44.4 (7.4)/45.4 (7.2) 27.56 (3.91)/26.59 (5.35) 5.42 (0.37)/5.37 (0.37) 5.01 (0.47)/4.74 (0.48)
FHS 886/1,110 54.7 (10.0)/54.1 (9.9) 27.85 (3.92)/26.13 (4.97) 5.24 (0.62)/5.25 (0.61) 5.36 (0.48)/5.14 (0.49
GenomeEUtwin 0/568 —/55.1 (21.8) —/24.6 (4.18) —/5.11 (0.68) —/5.24 (0.55)
HEALTH2000 580/625 49.1 (10.4)/51.7 (11.4) 25.69 (3.26)/25.32 (4.19) 5.22 (0.29)/5.06 (0.32) 5.34 (0.48)/5.17 (0.42)
Lolipop 582/188 53.2 (10.4)/51.2 (10.5) 27.49 (3.92)/26.74 (5.33) 5.05 (0.54)/5.34 (0.38) 5.51 (1.45)/5.35 (1.75)
LURIC 215/195 54.1 (12.6)/61.1 (11.1) 26.90 (3.60)/26.60 (4.00) 5.80 (0.60)/5.90 (0.60) —
KORA F3 711/751 62.3 (10.2)/61.6 (10.1) 27.89 (3.49)/27.70 (4.95) 5.30 (0.38)/5.33 (0.31) —
KORA S4 844/892 53.9 (8.9)/53.4 (8.8) 27.91 (3.87)/27.25 (4.89) 5.57 (0.46)/5.59 (0.45) —
METSIM 1,789/0 57.0 (7.3)/— 26.63 (3.76)/— 5.56 (0.32)/— —
NHANES III 468/746 51.3 (20.6)/51.4 (20.3) 26.92 (4.85)/26.37 (5.81) 5.38 (0.50)/5.15 (0.55) —
NTR 513/939 47.7 (14.4)/43.3 (13.7) 25.58 (3.28)/24.59 (4.02) 5.27 (0.46)/5.28 (0.45) 5.53 (0.51)/5.32 (0.51)
ORCADES 298/353 53.7 (15.3)/52.2 (15.4) 27.79 (4.14)/27.30 (5.11) 5.40 (0.49)/5.41 (0.51) 5.45 (0.51)/5.18 (0.49)
Partners/Roche 291/357 52.7 (12.9)/52.5 (12.7) 27.80 (5.20)/27.10 (7.30) 5.49 (0.48)/5.47 (0.45) —
PROCARDIS 687/144 60.5 (6.7)/62.8 (6.3) 27.65 (3.58)/28.11 (4.98) 5.98 (1.07)/6.17 (1.10) —
SardiNIA 1,418/1,928 46.5 (17.1)/45.2 (16.0) 26.36 (3.99)/24.65 (4.82) 5.47 (0.52)/5.39 (0.45) 4.96 (0.59)/4.67 (0.54)
SHIP 1,696/1,842 49.0 (16.0)/47.0 (16.0) 27.30 (3.90)/26.60 (5.20) 5.3 (0.60)/5.2 (0.60) —
Sorbs 254/376 46.6 (16.2)/46.4 (15.8) 26.90 (3.60)/26.7 (5.50) 5.35 (0.37)/5.36 (0.38) 5.47 (0.49)/5.21 (0.57)
SardiNIA stage2 555/890 46.4 (15.1)/46.3 (15.8) 26.36 (3.48)/24.61 (4.60) 5.45 (0.85)/5.31 (0.86) —
Segovia 274/309 53 (12)/55 (12) 27.35 (3.15)/27.41 (4.68) 5.17(0.49)/5.17 (0.45) —
Data are mean (SD). Fifteen cohorts were included in the fasting-glucose adjusted analysis shown in Table 2 (ARIC, BLSA, CROATIA,
Fenland, FHS, DESIR, GENOMEUTWIN, Lolipop, NTR, ORCADES, SardiNIA, KORA F4, DGI, Sorbs and Health2000). BLSA, DGI, Fenland,
FHS, KORA F4 and Sorbs were used for analyses that included 2-h glucose. The mean (mmol/l), SE and N for 2-h glucose levels for males
and females, respectively, were: 6.96 (2.47) (236)/6.42 (2.04) (207) in BLSA; 5.75 (1.20) (209)/6.15 (1.25) (254) in DGI; 5.27 (1.41) (600)/5.16
(1.35) (757) in Fenland, 5.744 (1.614) (858)/5.992 (1.707) (1,067) in FHS, and 5.19 (2.02) (254)/5.54 (1.96) (376) in Sorbs. Fasting glucose was
not available in KORA S4, thus conditional models were run in KORA F4, a follow-up visit of KORA S4 samples. Mean and SE 2-h glucose
levels in males and females, respectively, were: 5.66 (0.67)/5.60 (0.57) for HbA1C and 5.82 (1.20)/5.40 (1.01) for glucose. Cohorts in italics
provided only de novo genotyping data). The means for Hb (g/l, males/females) were 148.39 (10.29)/135.94 (9.55) (KORA F3), 148.21
(10.00)/134.51 (9.15) (KORA F4), 152.38 (11.33)/136.56 (10.38) (NHANES III) and 148.54 (12.12)/130.83 (11.60) (SardiNIA). The means for MCV
(pg, males/females) were 92.32 (3.91)/90.74 (4.08) (KORA F3), 92.04 (4.23)/90.83 (4.38) (KORA F4), 89.69 (4.45)/89.40 (4.34) (NHANES III) and
87.29 (9.28)/85.64 (9.22) (SardiNIA). The means for MCH (fl, males/females) were 31.22 (1.51)/30.60 (1.64) (KORA F3), 31.50 (1.62)/30.89 (1.73)
(KORA F4), 30.50 (1.74)/30.22 (1.67) (NHANES III) and 29.14 (3.60)/28.40 (3.69) (SardiNIA). The means for Iron (ı`mol/l, males/females) were
17.66 (5.34)/16.29 (5.25) (KORA F3), 22.41 (6.87)/20.53 (6.53) (KORA F4), 18.78 (6.53)/17.03 (6.96) (NHANES III) and 18.01 (6.23)/15.30 (5.98)
(SardiNIA). The means for Transferrin (g/l, males/females) were 2.45 (0.33)/2.56 (0.36) (KORA F3), 2.51 (0.35)/2.54 ( 0.38) (KORA F4), n.a.
(NHANES III) and 1.96 (0.52)/2.07 (0.579) (SardiNIA).
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cohort are shown in supplementary Table S1 in the online appendix
available at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0502/
DC1. Additional details on imputation and quality control applied by each
study are given in the online supplementary METHODS.
Primary genome-wide association studies and meta-analysis. In each
cohort a linear regression model was fit using untransformed (percentage)
HbA1c as the dependent variable to evaluate the additive effect of genotyped
and imputed SNPs. HbA1c showed a mild deviation from normality in the
majority of cohorts. Log-transformation did not significantly improve normal-
ity; nevertheless, such mild deviation did not result in an inflation of the test
statistics suggestive of an excess of false positives, as indicated by a genomic
correction  very close to the expected value of 1.0; thus, we report
untransformed (percentage) HbA1c results. The model was adjusted for age,
sex, and other cohort-specific variables as applicable. Further details are given
in the supplementary METHODS and supplementary Table S1. Regression
estimates for each SNP were combined across studies in a meta-analysis using
a fixed effect inverse-variance approach (justified by nonsignificant heteroge-
neity of effect sizes at all validated loci), as implemented in the METAL
software. The individual cohort analysis results were corrected prior to
performing the meta-analysis for residual inflation of the test statistic using
the genomic control method if the  coefficient was 1.0 (20). Cohort-specific
results for each of the 10 loci are given in supplementary Table S2. Hetero-
geneity across study-specific effect sizes was assessed using the standard 	2
test implemented in METAL, Cochran’s Q statistic and the I2 statistics (21).
Association with related traits and diseases. Secondary analyses were
carried out on 10 SNPs (rs2779116, rs552976, rs1800562, rs1799884, rs4737009,
rs16926246, rs1387153, rs7998202, rs1046896, and rs855791) reaching genome-
wide significance and including only the stronger of the 2 significant ANK1
SNPs (see supplementary METHODS for additional information). A first goal was
to detect “pleiotropic” effects on potentially related traits for the 10 loci. To
this end we tested them for association with correlated intermediate traits
(BMI, and glycemic and hematologic parameters, supplementary Table S3).
Further, we carried out association analyses of HbA1c levels conditional on
FG levels (Table 3) and hematologic parameters (supplementary Table S4) to
formally test mediation by glycemia or erythrocyte traits. Mediation is used
here to distinguish it from confounding. A confounder is a characteristic
associated with both exposure and outcome but is not on the causal pathway
linking the two together. By contrast, a mediator is also associated with both
exposure and outcome, but is on the causal pathway that may explain the
association between them. Our mediation analyses decompose the associa-
tion between a SNP and HbA1c into two paths. The first path links the SNP
directly to HbA1c, and the second path links the SNP to HbA1c through a
mediator, e.g., FG or hematologic parameters. A marked attenuation of the
size of effect on HbA1c of the SNP in the conditional “mediation” model implies
that the SNP (e.g., rs552976) acts on the mediator (e.g., FG), which in turn acts
on HbA1c levels. Further details on these analyses are provided in the on-line
supplementary METHODS.
Finally, we tested associations of the 10 loci with risk of type 2 diabetes or
coronary artery disease (CAD) using adequately powered case-controlled
meta-analyses. Association statistics with type 2 diabetes were obtained from
a previous analysis of the MAGIC datasets or from the DIAGRAM
 meta-
analysis (22). CAD associations were tested in this study using cohorts
described in supplementary Table S5. The CAD analytic sample size assem-
bled for this study had 80% power to detect associations at an  level of 5 
108 for a genotype relative risk of 1.14, and a risk allele frequency of 0.2.
Estimates of genetic effect size. We used several methods to evaluate the
size of the genetic effect of HbA1c-associated SNPs: 1) we used regression to
estimate in percentages the total variance in HbA1c explained by the 10 loci;
2) we calculated an additive genotype score based on the number of risk
alleles at 7 (nonglycemic) or 10 (all) loci and then calculated the difference in
HbA1c (%) between individuals in the top 10% of the genotype score distribu-
tion and those in the bottom 10% (supplementary METHODS); and 3) we used net
reclassification analysis to gauge the effect of individual genotype on HbA1c
distributions at the population level.
Net reclassification analysis. Variation in the measured level of HbA1c
associated with nonglycemic genetic effects may affect the classification of
individuals as diabetic or nondiabetic when screening general population
samples using HbA1c. We used this relationship as a way to understand the
clinical influence of the HbA1c loci when applied at the population level. We
estimated the change in classification that occurred when accounting for
effects of the seven loci presumed not to affect HbA1c via primarily glycemic
mechanisms (SPTA1, HFE, ANK1, HK1, ATP11A/TUBGCP3, FN3K, and
TMPRSS6) using the method of Pencina et al. (23). For this analysis we
combined the Framingham Heart Study (FHS), and Atherosclerosis Risk In
Communities (ARIC) European ancestry cohorts (N  10,110). ARIC and FHS
have several characteristics suitable for this analysis: 1) they are population-
based samples, thus allowing a test of diabetes screening in a truly unselected
sample; 2) they are of large sample size, thus maximizing the number of
diabetic subjects that can readily be folded back for reclassification analysis;
3) they have both fasting glucose and HbA1c measured. We excluded as in
previous analyses all individuals on diabetes treatment (diagnosed diabetes),
but retained individuals with FG 7.0 mmol/l not on treatment (who we
classified as having undiagnosed diabetes, N  593) as well as all nondiabetic
individuals (N  9,517). We then sought to differentiate these individuals on
the basis of their HbA1c levels, using 6.5% as the cutoff indicating diabetes.
We counted the cumulative frequency distribution of measured HbA1c levels
by diabetes status, then re-estimated the frequency distribution after regres-
sion analysis adjusting for the seven SNPs at the nonglycemic loci, recalibrat-
ing the distribution to have the same mean HbA1c as in each original cohort.
We counted the proportion of undiagnosed diabetic individuals with unad-
justed HbA1c 6.5% who had an adjusted HbA1c 6.5%, and the proportion of
nondiabetic individuals with unadjusted HbA1c 6.5% who had an adjusted
HbA1c 6.5%. The difference between these proportions is called “net reclas-
sification” and in this instance indicates the overall proportion of a population
whose diagnostic status would change based on the influence of these seven
common, nonglycemic genetic variants.
RESULTS
New common variants associated with HbA1c. We
carried out a meta-analysis of SNP associations with
HbA1c levels in up to 46,368 participants of European
ancestry from 31 cohorts. We identified 10 genomic re-
gions associated with HbA1c levels (Table 2, Figs. 1 and 2).
Six associated regions were new, including FN3K
(rs1046896, P 1.57 1026),HFE (rs1800562, P 2.59
1020), TMPRSS6 (rs855791, P  2.74  104), ANK1
(rs4737009, P  6.11  1012), SPTA1 (rs2779116, P 
2.75  109), and ATP11A/TUBGCP3 (rs7998202, P 
5.24  109). A second, independent SNP near ANK1 was
also associated with HbA1c (rs6474359, P 1.18 10
8; r2
with rs4737009 0.0001; see also supplementary METHODS).
In addition, SNPs in or near HK1 (rs16926246, P  3.11 
1054), MTNR1B (rs1387153, P  3.96  1011), GCK
(rs1799884, P  1.45  1020), and G6PC2/ABCB11
(rs552976, P  8.16  1018) were associated with HbA1c
levels. These loci had previously been associated with
HbA1c (15,16), FG (9–12,14,15) and/or type 2 diabetes risk
(9–12,15,16,19). Associations were generally similar
across cohorts, showing no significant heterogeneity (Ta-
ble 2). This lack of heterogeneity suggests that there is
good consistency in trait measurement across different
cohorts.
Pleiotropy and mediation of SNP-HbA1c associations.
HbA1c levels are influenced by average ambient glycemia
over the preceding 3 months, and possibly by erythrocyte
turnover. We therefore investigated the novel HbA1c loci
for associations with several diabetes-related and hemato-
logic quantitative parameters in the MAGIC cohorts
(19,24) (supplementary Table S4). As previously shown
(19), 3 of 10 loci, GCK, MTNR1B, and G6PC2, were
associated with FG and HOMA-B (an index of -cell
function, Table 3 and supplementary Table S3), and GCK
was additionally associated with 2-h glucose. In all cases,
the allele associated with increased HbA1c was also asso-
ciated with increased FG and 2-h glucose. No HbA1c-
associated SNP was significantly associated with
measures of insulin (supplementary Table S3). We further
used conditional models to investigate whether FG levels
mediated associations of SNPs with HbA1c. In these anal-
yses a marked attenuation of the effect size of the SNP in
a model adjusted for FG compared with the original main
effects model would be consistent with the hypothesis that
glycemic pathways primarily account for, or mediate, the
HbA1c association. For the three loci associated with FG
(GCK, MTNR1B, and G6PC2/ABCB11), effect sizes were
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substantially decreased in FG-conditioned models,
whereas at the other seven loci, effect sizes remained
essentially unchanged (Table 3), indicating that associa-
tions with HbA1c at these loci are unlikely to be mediated
by glycemic factors.
We also investigated associations of HbA1c loci with
several hematologic parameters in a subset of four popu-
lations with available data (KORA F3, KORA F4, SardiNIA,
and NHANES III, supplementary Table S3). Two HbA1c
loci (encoding for functional alleles at HFE and TM-
PRSS6) showed genome-wide significant association with
erythrocyte indexes, consistent with an influence of eryth-
rocyte physiology on HbA1c variability. The HbA1c-raising
alleles had diverse effects, including associations with
lower hemoglobin, mean corpuscular volume (MCV),
mean corpuscular hemoglobin (MCH) and iron, and higher
transferrin (HFE and TMPRSS6). In addition, three loci
(SPTA1, ANK1, and HK1) showed suggestive associations
(P  5  103) with erythrocyte indexes, with HbA1c-
raising alleles associated with increased MCV (SPTA1,
ANK1), or lower hemoglobin (HK1).
We used these same four cohorts where those parame-
ters were available to carry out a meta-analysis on HbA1c
levels, this time conditioning for the hematologic traits.
We did not observe any difference at the three “glycemic”
loci, although attenuation of  estimates was observed at
HFE, TMPRSS6, and HK1 (supplementary Table S4).
However, the sample size used for this analysis was
relatively underpowered, resulting in nonsignificant differ-
ences (P value  0.1) and we lacked power for other loci,
indicating the need for future analysis in larger sample
collections.
Associations with disease: type 2 diabetes and CAD
risk. HbA1c has been shown to have strong epidemio-
logic associations with type 2 diabetes risk and with
CAD risk in persons without diabetes. To ascertain if the
novel loci affected type 2 diabetes risk, we tested
associations in well-powered datasets. In a previous
meta-analysis of 40,655 type 2 diabetes cases and 87,022
controls in MAGIC (19), MTNRB1, and GCK showed
significant evidence of association (rs1387153 OR 
1.09, 95% CI 1.06–1.12, P  8.0  1013; rs1799884 OR 
1.07, 95% CI 1.05–1.10, P  5.0  108), whereas
G6PC2/ABCB11 did not (rs552976 OR  0.97, 95% CI
0.95–0.99, P  0.012). We tested the other novel loci
reported here for associations with type 2 diabetes in a
partly overlapping study of 8,130 cases and 38,987
controls from the DIAGRAM
 consortium (22) (supple-
mentary Table S3). No other locus associated with
HbA1c was associated with type 2 diabetes risk.
We also tested for associations with CAD using data
from nine case/control studies of European descent
(13,925 cases and 14,590 controls, supplementary Table
S5). None of the SNPs associated with HbA1c were asso-
ciated with CAD in the combined sample of 28,515 partic-
ipants (supplementary Table S6).
Effect size estimates for HbA1c-associated loci. In a
regression model, the 10 loci combined explained 2.4%
of the total variance in HbA1c levels, or about 5% of
estimated HbA1c heritability. We calculated a genotype
score using four of the largest population-based studies
(ARIC, SardiNIA, KORA F4, and FHS). Using the 10 HbA1c
loci, we estimated cohort-specific differences between the
top and bottom 10% of the genotype score distribution
(mean [SE] % HbA1c) to be: 5.25% (0.01) and 5.50% (0.004),
respectively (P  3.61  1033) for ARIC; 5.37% (0.027)
and 5.49% (0.027) (P  1.36  103) for SardiNIA; 5.32%
(0.024) and 5.58% (0.027) (P  4.64  1012) for KORA F4;
and 5.07% (0.046) and 5.38% (0.046) (P  1.45  106) for
FHS. The corresponding weighted average difference be-
tween the top and bottom 10% of the HbA1c distributions
was 0.21%. For a genotype score using only the seven
nonglycemic loci (FN3K, HFE, TMPRSS6, ANK1, SPTA1,
ATP11A/TUBGCP3, and HK1), the weighted average dif-
ference between the top and bottom 10% of the HbA1c
distributions was 0.19%.
Net reclassification in diabetes screening with HbA1c.
We used net reclassification analysis to estimate the
population-level impact of the seven nonglycemic loci
when HbA1c 6.5 (%) is used as the reference cutoff for
diabetes diagnosis, as recently proposed (18). We calcu-
lated the net reclassification around this threshold attrib-
utable to effects of the seven nonglycemic HbA1c loci that
might be expected when screening a general European
ancestry population for undiagnosed diabetes using
HbA1c. We studied the FHS and ARIC cohorts combined
(N  10,110), and included individuals with undiagnosed
diabetes for detection by screening. We compared the
TABLE 2
Associations with HbA1C of 10 independent loci identified in the meta-analysis
SNP Chr Pos (B36)
Nearest
locus
Effect/
other
allele
CEU
freq
(effect)
HbA1C (%) association Heterogeneity
Freq
(effect) N  (SE) P
	2 P
value Q P
I2
(%)
rs2779116 1 156,852,039 SPTA1 T/C 0.32 0.27 34,663 0.024 (0.004) 2.75 109 0.673 0.606 0
rs552976 2 169,616,945 G6PC2/ G/A 0.66 0.64 40,420* 0.047 (0.003) 8.16 1018 0.596 0.591 0
ABCB11
rs1800562 6 26,201,120 HFE G/A 0.96 0.94 43,778* 0.063 (0.007) 2.59 1020 0.661 0.300 11
rs1799884 7 44,002,308 GCK T/C 0.20 0.18 45,591* 0.038 (0.004) 1.45 1020 0.187 0.120 24
rs6474359 8 41,668,351 ANK1 T/C 0.97 0.97 29,997 0.058 (0.011) 1.18 108 0.328 0.267 15
rs4737009 8 41,749,562 ANK1 A/G 0.28 0.24 36,862 0.027 (0.004) 6.11 1012 0.182 0.182 21
rs16926246 10 70,763,398 HK1 C/T 0.89 0.90 42,707* 0.089 (0.004) 3.11 1054 0.329 0.162 21
rs1387153 11 92,313,476 MTNR1B T/C 0.28 0.28 32,293 0.028 (0.004) 3.96 1011 0.867 0.857 0
rs7998202 13 112,379,869 ATP11A/ G/A 0.15 0.14 34,724 0.031 (0.005) 5.24 109 0.415 0.383 6
TUBGCP3
rs1046896 17 78,278,822 FN3K T/C 0.25 0.31 45,953* 0.035 (0.003) 1.57 1026 0.450 0.440 2
rs855791 22 35,792,882 TMPRSS6 A/G 0.39 0.42 34,562 0.027 (0.004) 2.74 1014 0.970 0.962 0
*Indicates SNPs for which additional de novo genotyping was performed in eight cohorts. The  coefficient denotes the per-effect allele
increase in HbA1C (%) at that locus.
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measured distribution of HbA1c to the distribution ad-
justed for the seven nonglycemic SNPs (Fig. 3). The net
reclassification was 1.86% (P  0.002), indicating that
the population-level effect size of the 7 nonglycemic
HbA1c-associated SNPs is equivalent to reclassification of
about 2% of an European ancestry population sample
according to HbA1c-determined diabetes status.
DISCUSSION
HbA1c levels are influenced by ambient glycemia, and also
by erythrocyte biology, as seen in hereditary anemias and
iron storage disorders caused by rare, highly-penetrant
genetic variants. We analyzed associations of HbA1c levels
with common genetic variants associated in a meta-anal-
ysis of up to 46,000 nondiabetic individuals of European
descent from 31 cohorts. We identified 10 loci associated
with HbA1c at genome-wide levels of significance, with 1
locus, ANK1, showing 2 independent signals. Of these, six
(in or near FN3K, HFE, TMPRSS6, ATP11A/TUBGCP3,
ANK1, and SPTA1) represent new common genetic deter-
minants of HbA1c, and four (GCK, G6PC2/ABCB11,
MTNR1B, and HK1) are confirmatory (9–11; 13–16;
and 25).
Fasting and postprandial glucose levels are key deter-
minants of HbA1c. Of the 10 loci identified, those in GCK,
G6PC2, andMTNR1B were strongly associated with levels
of FG in this and previous studies (8; 10; 12–16; 19). Two
of them (GCK and MTNR1B) were also associated with
type 2 diabetes (19). Analyses conditioned on FG further
supported an effect on HbA1c via regulation of systemic
glucose concentrations for GCK, G6PC2, and MTNR1B
loci alone. No other HbA1c locus was associated with type
2 diabetes risk or quantitative type 2 diabetes risk factors,
suggesting that associations with HbA1c levels were not
likely to be mediated by ambient glycemia. Rare variants
at some of these loci (HK1, encoding hexokinase 1; ANK1,
ankyrin; SPTA1, spectrin) cause hereditary anemias, and
common variants at some loci are associated with quanti-
tative hematologic traits as well as HbA1c (25,26). This is
consistent with the hypothesis that these common variants
influence HbA1c levels via erythrocyte physiology. Specific
mechanisms are suggested by existing knowledge on the
function of leading candidate genes in each region (see the
supplemental on-line appendix).
HK1 is a good example to consider mechanism of action
of common variants, as it has confirmed support as a
true-positive HbA1c-associated locus (16,27) and rare vari-
ants in HK1 are associated with nonspherocytic hemolytic
anemia (MIM 142600) (28,29). HK1 encodes the erythro-
cyte isoform of hexokinase, which determines the intra-
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cellular commitment of glucose to the glycolytic pathway
by catalyzing the conversion of intracellular glucose to
glucose-6-phosphate. One plausible explanation for the
observed association lies in the potential dissociation
between ambient plasma glucose and intracellular cyto-
plasmic glucose that might be induced by functional
variants at HK1; since the enzyme is preferentially active
in erythrocytes, the intracellular utilization (metabolism)
of glucose may not be reflective of systemic levels of
glycemia. In support of this notion, the HbA1c-raising allele
was not associated with any glycemic traits in another
recent study of European cohorts, but had robust associ-
ations with lower hemoglobin and hematocrit (27). In the
CHARGE consortium, common variants in HK1 were
associated with decreased hemoglobin (25). We postulate,
therefore, that the hemoglobin-lowering variant may affect
the overall percentage of HbA1c through an increased
glucose/hemoglobin molar ratio, which in turn could in-
crease the rate of hemoglobin that is glycated at a given
glucose level. Variation in rates of deglycation and of
erythrocyte turnover also are likely to play an important
role in measured HbA1c levels. These hypotheses require
further testing. A possible role of erythrocyte membrane
stability and altered erythrocyte life span (ANK1, SPTA1)
and hemoglobin deglycation (FN3K) may be postulated
based on the known function of the respective gene
products (supplementary online appendix).
A role for iron homeostasis influencing HbA1c is sug-
gested by the HFE and TMPRSS6 loci, where associations
were observed at known functional variants in two com-
plementary and directionally consistent pathways (30). At
HFE the A allele at rs1800562 (Cys262Tyr), which is
responsible for hereditary hemochromatosis (MIM
235200), was associated with lower levels of HbA1c, rather
than the higher levels one would predict from epidemio-
logic observations of the increased HFE mutation preva-
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lence in patients with type 2 diabetes (31,32). This
apparently paradoxical relationship may be due to a shift
in glucose to hemoglobin molar ratio associated with
higher overall hemoglobin (supplementary Table S3), lead-
ing to consequent decrease in the percentage of glycated
hemoglobin. The reciprocal observation is seen for TM-
PRSS6, where the A allele at SNP rs855791 (Val736Ala)
was associated with lower hemoglobin levels and higher
HbA1c levels, as one would predict in a state of iron
deficiency and disproportionately lower total hemoglobin
concentrations.
It is known that conditions characterized by altered
erythrocyte physiology may influence the utility of HbA1c
in diabetes diagnosis (2–4,18), although this has generally
been attributed to specific pathologies, such as inherited
hemoglobinopathies, rather than to physiologic variation
in the general population. We show here for the first time
that the common genetic variation resulting in subtler but
more widespread alteration of iron levels or hemoglobin
concentration can also affect HbA1c levels. The absolute
size of the genetic effect of 7 to 10 common SNPs
associated with HbA1c is about 0.2%, comparing the ex-
tremes of the HbA1c-raising allele distribution. This is
smaller than the 0.5% HbA1c average intralaboratory vari-
ation for HbA1c-certified labs reported as of 2000 (33). We
sought to frame these genetic effects in population-level
terms by comparing HbA1c distributions without and with
adjustment for the seven nonglycemic SNPs and calculat-
ing net reclassification around the 6.5% HbA1c diagnostic
threshold. We found the overall effect of the nonglycemic
loci identified in this study to be small but detectable,
potentially affecting about 2% of white individuals likely
reclassified by diabetes status. This estimate represents an
upper boundary for the effect of these common variants,
as most people (the majority in the center of the distribu-
tion) are expected to have a smaller individual genotype
effect size.
Our findings are therefore directly relevant to recent
initiatives to focus diabetes diagnosis and care more
centrally on HbA1c. Although the 10 loci described here
likely represent the strongest common association signals
found in Europeans, they account for a relatively small
proportion of total variance of HbA1c and have minimal
effect on diagnosis or misclassification of diabetes. There-
fore, our study achieves a significant result in quantifying,
for the first time, the misclassification risk associated with
the top tier of HbA1c-associated common genetic variation.
Future research will be required to explore two main areas
not addressed in this study. First, genetic association studies
in diabetic individuals will be important to assess the contri-
bution of HbA1c-associated variants to its application in
diabetes control. These analyses require different study de-
signs to ours, and are beyond the scope of current datasets.
Second, it will be important to explore associations of HbA1c
with low to intermediate frequency variants through imputa-
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For instance, among individuals with undiagnosed diabetes, 39.5% had an unadjusted HbA1c level >6.5 (%) and 37.4% had a seven SNP-adjusted
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tion from the 1,000 Genomes Project, direct association using
whole-genome sequencing data, and in-depth replication and
locus fine-mapping through custom arrays.
Finally, it will be important to evaluate reclassification
rates in different populations, because the allele frequen-
cies of some SNPs shown to be associated with HbA1c are
known to vary substantially among populations with dif-
ferent ethnic ancestries. For instance, the A allele fre-
quency at rs1800562 (HFE) in populations of European
ancestry is 5% (CEU), but the A allele is absent in
populations of African or East Asian ancestry (YRI, CHB/
JPT). The T allele frequency at rs855791 (TMPRSS6) is 39%
in CEU samples, but only 11 and 5% in the YRI and
CHB/JPT samples, respectively. It will therefore be impor-
tant to assess how variation in frequency and effect size
influence the impact of HbA1c-associated variants in di-
verse populations.
In summary, in a meta-analysis of GWAS in a large
number of individuals of European ancestry, we identified
10 common genetic loci associated with HbA1c levels. Six
of these loci are novel, and seven appear to influence
HbA1c via nonglycemic erythrocyte and iron biologic path-
ways. The genetic effect size of this set of loci on varia-
tions in HbA1c levels is small, but carries a detectable
reclassification risk that will need to be refined by the
discovery of additional variants and testing in diverse
ancestral populations.
URLs. METAL, http://www.sph.umich.edu/csg/abecasis/
Metal/index.html; HapMap, http://www.hapmap.org; R-
project, http://www.r-project.org; 1,000 Genomes Project,
http://www.1000genomes.org.
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